On 6 July 2026, Novartis and Myricx Bio announced that they have entered into an agreement for the acquisition of Myricx Bio by Novartis. Myricx Bio is a UK-based biotechnology company developing antibody-drug conjugates (ADCs) using N-myristoyltransferase inhibitor (NMTi) payloads. Myricx has two lead assets under development, with potential across multiple solid tumour settings.
The transaction is expected to close in H2 2026, subject to closing conditions and regulatory approvals. Under the terms of the agreement, Novartis will pay Myricx Bio USD1.1 billion cash up front, with up to USD400 million in potential milestone payments.
According to the companies, the acquisition of Myricx Bio will strengthen Novartis’ oncology pipeline, as ADCs have become an important part of cancer treatment. Fiona Marshall, the President of Biomedical Research at Novartis stated that the “proposed acquisition reflects our strategy to scale innovative platforms, as we have with radioligand therapies, to deliver more durable, transformative treatments for patients.”
In February 2024, Novartis announced that it had agreed to acquire MorphoSys AG, a biopharmaceutical company focused on oncology medicines, for around €2.7B.